Will Spooren, Ph.D.

Section Head, Behavioural Pharmacology and Preclinical Imaging, F. Hoffmann-La Roche

SFARI Investigator Website

Will Spooren is section head of behavioral pharmacology and preclinical imaging at Hoffman-La Roche. His group is responsible for providing in vivo characterization of drug candidates through the course of drug discovery an`d development process. He co-led the European Autism Interventions – A Multicentre Study for Developing New Medications (EU-AIMS) with Declan Murphy and currently serves as the industry project lead in the Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials).

Funded Projects

Autism Innovative Medicine Studies-2-Trials (AIMS-2-Trials): A large-scale collaborative autism research project

Awarded: 2018
Award Type: Research

SFARI Funded Publications

Imbalanced social-communicative and restricted repetitive behavior subtypes of autism spectrum disorder exhibit different neural circuitry. Bertelsen N., Landi I., Bethlehem R.A.I., Seidlitz J., Busuoli E.M., Mandelli V., Satta E., Trakoshis S., Auyeung B., Kundu P., Loth E., Dumas G., Baumeister S., Beckmann C.F., Bölte S., Bourgeron T., Charman T., Durston S., Ecker C., Holt R.J., Johnson M., Jones E., Mason L., Meyer-Lindenberg A., Moessnang C., Oldehinkel M., Persico A., Tillmann J., Williams S.C.R., Spooren W., Murphy D., Buitelaar J.K., EU-AIMS LEAP Group, Baron-Cohen S., Lai M.-C., Lombardo M.

Comprehensive analysis of two Shank3 and the Cacna1c mouse models of autism spectrum disorder. Kabitzke P., Brunner D., He D., Fazio P.A., Cox K., Sutphen J., Thiede L., Sabath E., Hanania T., Alexandrov V., Rasmusson R., Spooren W., Ghosh A., Feliciano P., Biemans B., Benedetti M., Luo Clayton A.

Comprehensive analysis of the 16p11.2 deletion and null CNTNAP2 mouse models of autism spectrum disorder. Brunner D., Kabitzke P., He D., Cox K., Thiede L., Hanania T., Sabath E., Alexandrov V., Saxe M., Peles E., Mills A., Spooren W., Ghosh A., Feliciano P., Benedetti M., Luo Clayton A., Biemans B.